tiprankstipranks
Windtree Therapeutics Appoints Jed Latkin as New CEO
Company Announcements

Windtree Therapeutics Appoints Jed Latkin as New CEO

Don't Miss Our Christmas Offers:

Windtree Therapeutics ( (WINT) ) has provided an update.

Windtree Therapeutics, Inc. announced the retirement of Craig Fraser as CEO, effective December 2024, with Jed Latkin set to take over the role. Latkin, who brings extensive experience in finance and biotech from his previous roles at ProPhase Labs and other companies, will assume leadership with a focus on leveraging his expertise to drive the company forward. His compensation package includes bonuses and equity incentives, reflecting the company’s commitment to aligning executive interests with shareholder value.

For an in-depth examination of WINT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyWindtree Therapeutics announces presentation highlighting istaroxime
TheFlyWindtree Therapeutics announces new istaroxime patent filing
TheFlyWindtree Therapeutics announces partnership with New Growth Advisors
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App